JP2015523382A - メトホルミンの三塩形態 - Google Patents

メトホルミンの三塩形態 Download PDF

Info

Publication number
JP2015523382A
JP2015523382A JP2015521784A JP2015521784A JP2015523382A JP 2015523382 A JP2015523382 A JP 2015523382A JP 2015521784 A JP2015521784 A JP 2015521784A JP 2015521784 A JP2015521784 A JP 2015521784A JP 2015523382 A JP2015523382 A JP 2015523382A
Authority
JP
Japan
Prior art keywords
metformin
acid
compound
compound according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015521784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523382A5 (enExample
Inventor
ミラリ，バナヴァラ・エル
シャヴォリーノ，フランク・シー
Original Assignee
テティス・ファーマシューティカルズ・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,970 external-priority patent/US8765811B2/en
Application filed by テティス・ファーマシューティカルズ・エルエルシー filed Critical テティス・ファーマシューティカルズ・エルエルシー
Publication of JP2015523382A publication Critical patent/JP2015523382A/ja
Publication of JP2015523382A5 publication Critical patent/JP2015523382A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2015521784A 2012-07-10 2013-07-10 メトホルミンの三塩形態 Pending JP2015523382A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261669763P 2012-07-10 2012-07-10
US61/669,763 2012-07-10
US201261670368P 2012-07-11 2012-07-11
US201261670376P 2012-07-11 2012-07-11
US61/670,376 2012-07-11
US61/670,368 2012-07-11
US13/841,970 2013-03-15
US13/841,970 US8765811B2 (en) 2012-07-10 2013-03-15 Tri-salt form of metformin
PCT/US2013/049984 WO2014011814A1 (en) 2012-07-10 2013-07-10 Tri-salt form of metformin

Publications (2)

Publication Number Publication Date
JP2015523382A true JP2015523382A (ja) 2015-08-13
JP2015523382A5 JP2015523382A5 (enExample) 2016-08-18

Family

ID=49916541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015521784A Pending JP2015523382A (ja) 2012-07-10 2013-07-10 メトホルミンの三塩形態

Country Status (12)

Country Link
EP (1) EP2872483A4 (enExample)
JP (1) JP2015523382A (enExample)
KR (1) KR20150036235A (enExample)
CN (1) CN104684889A (enExample)
AU (1) AU2013290168A1 (enExample)
BR (1) BR112015000368A2 (enExample)
CA (1) CA2878819A1 (enExample)
IL (1) IL236613A0 (enExample)
IN (1) IN2015KN00076A (enExample)
MX (1) MX2015000408A (enExample)
WO (1) WO2014011814A1 (enExample)
ZA (1) ZA201500274B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7005071B1 (ja) 2021-03-30 2022-01-21 ▲広▼州大学 メトホルミン塩の調製方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124141A1 (en) * 2013-02-07 2014-08-14 Mylari Banavara L Metformin derivatives for treating diabetes
EP3140316A1 (en) 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
EP3157936B1 (en) * 2014-06-18 2018-10-17 Thetis Pharmaceuticals LLC Mineral amino-acid complexes of active agents
US20170119841A1 (en) * 2015-11-04 2017-05-04 Thetis Pharmaceuticals Llc Amino acid salts of unsaturated fatty acids
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
US10471963B2 (en) 2017-04-07 2019-11-12 TuSimple System and method for transitioning between an autonomous and manual driving mode based on detection of a drivers capacity to control a vehicle
US10737695B2 (en) 2017-07-01 2020-08-11 Tusimple, Inc. System and method for adaptive cruise control for low speed following
CN114349665B (zh) * 2021-11-30 2023-06-09 潍坊博创国际生物医药研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用
CN115192625A (zh) * 2022-06-30 2022-10-18 山东海赜生物科技有限公司 一种口服组合物

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525361A (ja) * 1997-12-08 2001-12-11 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
JP2006520335A (ja) * 2003-03-18 2006-09-07 ノバルティス アクチエンゲゼルシャフト 脂肪酸とアミノ酸を含有する組成物
JP2007528886A (ja) * 2004-03-12 2007-10-18 フルニエ ラボラトリーズ アイルランド リミテッド 肥満の治療又は予防用のメトホルミン及びオルリスタットの使用
WO2009080022A1 (en) * 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum tablet
WO2009151116A1 (ja) * 2008-06-13 2009-12-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
WO2010127099A2 (en) * 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
JP2010539229A (ja) * 2007-09-21 2010-12-16 ハンオル バイオファーマ カンパニー，リミテッド Ｎ，ｎ−ジメチルイミドジカルボンイミド酸ジアミドのジカルボン酸塩、その製造方法、及びその薬剤学的組成物
US20120094942A1 (en) * 2010-10-19 2012-04-19 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US20140221467A1 (en) * 2013-02-07 2014-08-07 Banavara L. Mylari Metformin derivatives for treating diabetes and diabetes complications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2774591B1 (fr) * 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
AU2001213150A1 (en) * 2000-08-03 2002-02-18 Olga Evgenievna Kolesova Composition of metformin with succinic acid or salts thereof and method for treating diabetes
US8796338B2 (en) * 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525361A (ja) * 1997-12-08 2001-12-11 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
JP2006520335A (ja) * 2003-03-18 2006-09-07 ノバルティス アクチエンゲゼルシャフト 脂肪酸とアミノ酸を含有する組成物
JP2007528886A (ja) * 2004-03-12 2007-10-18 フルニエ ラボラトリーズ アイルランド リミテッド 肥満の治療又は予防用のメトホルミン及びオルリスタットの使用
JP2010539229A (ja) * 2007-09-21 2010-12-16 ハンオル バイオファーマ カンパニー，リミテッド Ｎ，ｎ−ジメチルイミドジカルボンイミド酸ジアミドのジカルボン酸塩、その製造方法、及びその薬剤学的組成物
WO2009080022A1 (en) * 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum tablet
WO2009151116A1 (ja) * 2008-06-13 2009-12-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
WO2010127099A2 (en) * 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US20120094942A1 (en) * 2010-10-19 2012-04-19 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US20140221467A1 (en) * 2013-02-07 2014-08-07 Banavara L. Mylari Metformin derivatives for treating diabetes and diabetes complications

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7005071B1 (ja) 2021-03-30 2022-01-21 ▲広▼州大学 メトホルミン塩の調製方法
JP2022155436A (ja) * 2021-03-30 2022-10-13 ▲広▼州大学 メトホルミン塩の調製方法

Also Published As

Publication number Publication date
AU2013290168A1 (en) 2015-02-05
MX2015000408A (es) 2015-07-14
IL236613A0 (en) 2015-02-26
KR20150036235A (ko) 2015-04-07
EP2872483A4 (en) 2016-03-16
IN2015KN00076A (enExample) 2015-07-31
CA2878819A1 (en) 2014-01-16
EP2872483A1 (en) 2015-05-20
BR112015000368A2 (pt) 2017-06-27
WO2014011814A1 (en) 2014-01-16
CN104684889A (zh) 2015-06-03
ZA201500274B (en) 2017-10-25

Similar Documents

Publication Publication Date Title
JP2015523382A (ja) メトホルミンの三塩形態
TWI621624B (zh) 合成的三萜系化合物及其使用於治療疾病之方法
US8933124B2 (en) Tri-salt form of metformin
SK14922002A3 (sk) Farmaceutický prostriedok na prevenciu, zlepšenie a/alebo liečenie diabetickej komplikácie a použitie postprandiálnej látky na zníženie hladiny krvného cukru
JP2013516461A (ja) ビグアニド誘導体、その製造方法及びこれを有効成分として含有する薬学組成物
JP2006512334A (ja) Ｄｐｐ−ｉｖ阻害剤とｐｐａｒ−アルファ化合物の組み合わせ
EA013973B1 (ru) Способы лечения кожной волчанки при помощи аминоизоиндолиновых соединений
JP5788527B2 (ja) キナーゼ阻害剤の副作用低減剤
WO2020177587A1 (zh) 治疗脂肪性肝病和/或脂肪性肝炎的方法
WO2014008374A2 (en) Combination therapies comprising metformin salts and antihyperglycemia agents or antihyperlipidemia agents
TW516959B (en) Composition containing ascorbic acid
US9382187B2 (en) Tri-salt form of metformin
US20120295973A1 (en) Methods and compositions of derivatives of probucol for the treatment of diabetes
US9815777B2 (en) Metformin salts to treat Type2 diabetes
KR20230136627A (ko) 포유 동물에서 체중 감소를 유도하기 위한 외인성 케톤 에스테르의 용도
US20240374546A1 (en) Uses and methods for promoting increased mitochondrial mass and function
WO2014008379A2 (en) Diamine and meglumine salt forms of fatty acids
US20080280985A1 (en) Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
TW201818964A (zh) 使用色胺酸羥化酶抑制劑之方法
TW201731506A (zh) 糖尿病治療劑之倂用
WO2001034134A2 (en) Oncolytic combinations for the treatment of cancer
US20130317034A1 (en) Combination therapy for treating diabetes
EP1547614B1 (en) Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof
WO2015134357A1 (en) Modulators of insulin receptor
TW200539859A (en) Methods for increasing neurotransmitter levels using hydroxycitric acid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170612

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170615

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180119